Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
AhR activators - friend or foe? - Hypha Discovery Blogs
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
Roquinimex - wikidoc
Laquinimod - an overview | ScienceDirect Topics
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
PDF) Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Laquinimod - Wikipedia
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
laquinimod
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Active Biotech regains rights of laquinimod from Teva
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Teva drops development of laquinimod - PharmaTimes
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
